/

Batteries & E-Mobility

/

Gyre Therapeutics

Gyre Therapeutics

Gyre Therapeutics

Verified Nov 2026

Batteries & E-Mobility

·

United States flag

San Diego, California

·

Since

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, California, with 500–1,000 employees and estimated revenue of $100–250 million. The company develops small-molecule anti-inflammatory and anti-fibrotic therapies for organ fibrosis and inflammatory diseases, serving the automotive, electric-vehicle, and medical sectors. It completed an acquisition of Cullgen in May 2026 to establish an integrated biopharmaceutical operation spanning the United States and China.

Gyre Therapeutics

Verified Nov 2026

AT A GLANCE

Founded

Headquarters

United States flag

San Diego, California

Employees

500-1,000

Ownership

Gyre Therapeutics at a glance

Revenue

$100-250M

Est. band

Employees

500-1,000

Headquarters

San Diego, California

Industries

Automotive

Electric Vehicles

Medical

Overview

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, California, with 500–1,000 employees and estimated revenue of $100–250 million. The company develops small-molecule anti-inflammatory and anti-fibrotic therapies for organ fibrosis and inflammatory diseases, serving the automotive, electric-vehicle, and medical sectors. It completed an acquisition of Cullgen in May 2026 to establish an integrated biopharmaceutical operation spanning the United States and China.

At a glance

Attribute

Detail

Headquarters

San Diego, California

Employees

500-1,000

Revenue

$100-250M (estimated)

Primary capability

Batteries & E-Mobility

What Gyre Therapeutics makes

Gyre's pipeline includes Hydronidone, a small-molecule candidate for liver fibrosis, and ETUARY®, an approved treatment for Idiopathic Pulmonary Fibrosis marketed in China.

Latest developments

Facilities

Gyre Therapeutics is headquartered in San Diego, California. Public sources also reference these locations:

Company details

The company went public on Nasdaq under the ticker GYRE on October 31, 2023, and maintains a controlling interest in Beijing Continent Pharmaceuticals. Gyre Therapeutics has an estimated 500-1,000 employees, and is headquartered in San Diego, California.

Frequently asked questions

What does Gyre Therapeutics make?

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, California, with 500–1,000 employees and estimated revenue of $100–250 million. The company develops small-molecule anti-inflammatory and anti-fibrotic therapies for organ fibrosis and inflammatory diseases, serving the automotive, electric-vehicle, and medical sectors. It completed an acquisition of Cullgen in May 2026 to establish an integrated biopharmaceutical operation spanning the United States and China.

Where is Gyre Therapeutics headquartered?

Gyre Therapeutics is headquartered in San Diego, California (12770 High Bluff Dr, San Diego, California, 92130-2057).

How big is Gyre Therapeutics?

Gyre Therapeutics has an estimated 500-1,000 employees, with revenue in the $100-250M range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

San Diego, California (HQ)Headquarters · United States
San Diego, California (HQ)12770 High Bluff Dr, San Diego, California, 92130-2057, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.